The chair of medicine who won't retire tests a hospital's succession

The office of the chair of medicine at Ptolemaic General Hospital in Alexandria has a nameplate that hasn't changed in nineteen years. That's roughly nineteen years longer than the bylaws anticipated when they were written.

Dr. Ines Marchetti runs the largest clinical department on the Egyptian coast. By every metric her institution tracks, she is excellent at it. She is also, by the count of the people arranged in a neat organizational tree beneath her, the reason none of them will run anything soon.

"There was a plan," said Dr. Osei Nwachukwu, one of three deputy chairs whose promotion tracks were tied to a handover that was scheduled, announced, and then quietly withdrawn last spring. "The plan assumed a date. The date assumed a body that ages. Neither assumption survived contact with the Meridian protocols."

Marchetti, who began a course of senescence-slowing therapy through a Meridian Longevity Institute partner clinic four years ago, declined a planned step-down this year. She was within her rights. That's the whole problem.

The bylaws that never imagined this

The hospital's governing charter, ratified before longevity therapy left the trial wards, sets no mandatory retirement age for department heads. It didn't need to. When it was written, biology enforced succession on a reliable schedule, and administrators could plan around the actuarial tables the way farmers plan around rain.

The rain has stopped. Ptolemaic General's board reviewed the succession language twice in the past two years and adjourned both times without a vote. Anyone who's watched the Assembly of Signatories arrive one crisis behind consensus will recognize the pattern.

"You cannot retroactively install a step-down clause and call it neutral," said Fenella Cruz, who chairs the board's governance committee. "It reads as a clause aimed at one person, because right now it is aimed at one person. So we do nothing, which is also a decision. I am aware."

Marchetti is unapologetic, in the manner of someone who has heard the argument before and finds it unconvincing. "I am asked to leave for reasons that have nothing to do with my competence and everything to do with my calendar," she told me in her office. "When my judgment fails, remove me. Until then, the demand is that I vacate a post I am good at so the queue can advance. That is a fine argument about queues. It is a poor argument about medicine."

The chart tells a different story about the queue.

The caseload the next generation trains for but doesn't touch

Since grown-organ surgery became routine, the department's operative volume has roughly doubled. Printed hearts, grown pancreases, the whole catalog that ended the waitlists — attendings in their thirties and forties, who trained on exactly these procedures, handle nearly all of it, and they perform them daily.

What they don't do is decide. Protocols, hiring, the allocation of theater time, the department's vote in the regional health compact: all of it flows upward to a leadership cohort that trained in an era when a transplant meant a line, and a funeral somewhere upstream when the line moved too slowly.

"I have done more grown-organ transplants than my chair has seen," said Dr. Amira Khaled, a senior attending who has been eligible for a deputy track for six years. "I am trusted with the patient. I am not trusted with the schedule. The reasoning is that I lack seniority. Seniority, it turns out, is the one thing therapy now lets you accumulate without limit."

The deputies below Marchetti have begun, quietly, to interview elsewhere — at newer institutions in the Lunar Districts, and at Meridian, where the charters were written recently enough to include step-down language. Not incidentally, Meridian is also the outfit selling the very therapy that froze the ladder on Earth in the first place.

Dr. Nwachukwu has one such interview scheduled for the next transfer window. He was frank about the irony. "I am leaving a hospital because my chair took the treatment," he said, "to go work for the people who sold it to her."

Marchetti's next therapy review is in the spring. She intends to renew.

A body that never replaces its old cells gets cancer. I don't know that an institution that never replaces its old leaders gets something identical, but I've started watching Ptolemaic General the way I'd watch a scan I didn't like the look of. We haven't grown the therapy for that one. Given who's in charge of growing therapies, I'm not sure we're going to.